| 
                                    Even in well designed
                                    studies there are
                                    limits of entailment, and these limits are often shoved aside by a press more
                                    concerned with ratings than the truth, and with pleasing advertisers.  For
                                    example both New Week and Time Magazines--two of the best sources in the
                                    popular press for medical news published articles advising the discontinuation
                                    of HRT (hormone replacement therapy) for women based on the WHI (Women’s
                                    Health Initiative 1991-2002, see bottom of page for details) study that showed an
                                    increased incidents of breast cancer (had been known for over 4 decades) and a surprising
                                    increase in cardiac events.  What was known and not considered, the
                                    financial  gains for Big PhARMA for getting
                                    women
                                    off of generic HRT (a topic developed below). 
                                    Major defects in the WHI studies were not given proper press.   In an effort to
                                    right the record Dr
                                    Robert Langer, UCSD Professor of Medicine, spoke in November of 2002 before an
                                    audience of medical students about the WHI study, which he was involved in
                                    (the talk was broadcasted on UCSD channel in December).  He used for both
                                    his introduction and summation the articles in Time and Newsweek about
                                    WHI, especially the conclusions they drew.  It provided an avenue for
                                    him to discuss other studies and limits  upon conclusions that could be drawn
                                    from the WHI, limits violated by these two magazines.  Times article The
                                    Truth about Hormones, 7/22/02, was short on truth, so too the Newsweek
                                    article.  They noted that one portion of the study was stopped because of
                                    health consequences from the use of Prempro, but failed to note the large body
                                    of research which showed very significant benefits for other forms of estrogen
                                    used with progesterone or used estrogen unopposed.  Doctor Langer discussed these alternatives,
                                    among other things.       Time's article failed
                                    for 4 major
                                    reasons and numerous minor ones.  First and fundamental failure was that
                                    the very study was designed to fail because it used a combo of hormones (equine
                                    estrogen & MPA) were known prior to be atypically ineffective (see “Setup
                                    to Fail” below for details). Second the results for Prempro (the hormone
                                    combination of equine estrogen and medroxyprogesterone) cannot be generalized
                                    to other HRTs, namely esterified estrogen alone and estrogen with progesterone. 
                                    Third the increased risk in breast cancer was caused by MPA (medroxyprogesterone--see
                                    article below).  And fourth, since the
                                    study was of menopausal women, it could not be applied to postmenopausal women
                                    or the effects of such women using long-term HRT.  For example for
                                    post menopausal women using good HRT for 10 years reduced Alzheimer’s disease
                                    83%, also breast cancer and thrombosis (supporting studies below).  These limits of the WHI study and more were
                                    brought before the audience at UCSD by Doctor Langer. With distant glasses
                                    a look at the
                                    performance of the pharmaceutical industry reveals that they replace inexpensive
                                    off-patent drugs with new patented, expensive drugs, especially for health
                                    issues which can produce what the industry terms “a block buster.”   This has been done over and over
                                    again.  One block buster, the treatment for
                                    osteoporosis with the class of drugs bisphosphonates, has as a competitor the
                                    much more effective estrogen.  The near
                                    elimination of the use of estrogen to prevent & treat osteoporosis has
                                    produced billions in profits. 
                                    Significant profits are also derived from treating other age related
                                    conditions that would have been less frequent if a different HRT was used then
                                    Prempro.  This is a serious abuse of
                                    trust.  Other examples corporate greed occurs
                                    with the replacing of diuretics with patented drugs for the control of blood
                                    pressure, and the use of aspirin as an arthritic medication.  This website contains a detailed examination
                                    of the COX-2 inhibitors such as VIOXX and the efforts of Merck to keep it
                                    adverse consequences hidden (an estimated 55,000 deaths and 125,000 strokes and
                                    heart attacks prior to its being pulled). 
                                    As the article below “Setup to Fail” argues the choice of drugs for the
                                    WHI was done knowingly.    There is a large body of research on HRT, which help
                                    put the WHI in proper perspective.  For HRTs other than Prempro by Wyeth the results depend on the progestogen used.  With progesterone there was no
                                    increase (see
                                    French study below).   With
                                    Prempro
                                    there is a significant increase in blood clots, heart attacks, breast
                                    cancer, and Alzheimer’s disease. For all HRTs with progesterone there is a
                                    decrease in the rate of colon cancer, heart attacks, osteoporosis, and
                                    Alzheimer’s disease (see page 1).  Given these differences in HRT, it
                                    speaks poorly of the FDA that Prempro is still available and widely used.  Of
                                    particular importance was a study that compared statins to either estrogen or
                                    estrogen and prostaglandin.  Statins are given to women with high levels
                                    of cholesterol and low-density lipoproteins.  These women had done just as
                                    well if given either estrogen or estrogen and progesterone instead of a statin
                                    in improving their lipid profile.  Since statins have some serious side
                                    effects and none of the additional benefits of estrogen, estrogens should be
                                    the treatment of choice.  Unfortunately, the Prempro therapy does not
                                    confer these benefits.   There are 3 immediate reasons for HRT therapy. 
                                    One is the control of hot flashes.  Second are cosmetic and psychological
                                    reasons:  the skin remains suppler, breasts firmer, memory improved,
                                    and less depressions.  All these effect self-esteem and thus quality of
                                    life.  Third is sexual performance:  the control of vaginal dryness
                                    and the wall of the vagina is thicker.  Medical intervention for social
                                    and psychological benefits is common in our society.   There are many
                                    older long-term benefits (well beyond the scope of the WHI) that show very
                                    significant reduction of Alzheimer’s, of atherosclerosis, of heart attacks, of
                                    osteoporosis, of colon cancer, no increase in breast cancer, and a reduction of
                                    THROMBOSIS with esterfied estrogen with progesterone (see studies below, and on
                                    this website http://healthfully.org/fhr/). 
                                    When one adds to this the cosmetic and sexual advantages plus the managing of
                                    hot flashes, the choice is crystal clear.  Because of its common usage as contraception
                                    for over 50 years, the use of female hormones has been the best studied of all
                                    drugs. There is enough data available to put to rest any of the Big PhARMA
                                    generated uncertainties over HRT treatment.    Because of the
                                    complexities of issues and the limited time that health professional have to
                                    review studies and keep abreast of new treatments, they look to “opinion
                                    makers” and follow accepted practices.  Medical
                                    societies such as the American Heart Association also receive significant
                                    “donations” from Big PhARMA; the same for medical schools. The industry selects
                                    directly or indirectly researchers for their studies, and thus who will become
                                    “opinion makers”.   We have corporate medicine.  The harm done is incredible.  Millions of
                                    women have died early because they
                                    have discontinued (or not started) HRT due to incorrect coverage in the
                                    popular press and the role of Big PhARMA in changing the once very common
                                    practice of managing the side effects of menopause and post menopause, and of
                                    treating & preventing osteoporosis with HRT.   Every aspect of
                                    medical science and treatment has been compromised by corporate medicine.  This website along with worstpill.org attempt
                                    to address the misinformation--BY JK.  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 
                                    Setup to Fail: http://www.nature.com/news/2010/100907/full/news.2010.453.html#comment-id-13486  Published in the highly acclaimed science journal Nature September 2010  Prempro  (Premphase) is conjugated Estrogens
                                    (.625 mg) & Medroxyprogesterone acetate (2.5 mg)----jk emphasis: 
                                    2010-09-09 12:24:18
                                    AM    Posted by: Anna Michaels, PhD     #13486
                                      Millions of women took a mix of the hormones
                                    oestrogen  and progesterone called Prempro. Is Nature ignorant of
                                    the vital fact that Prempro contains no progesterone,
                                    but instead the artificial progestogen Provera? The other component
                                    is Premarin (conjugated estrogen), which is a very uncertain, patent mixture of substances from the urine of pregnant mares. Whilst that in no way invalidates the main point of the report, or the research, indeed the it makes the need for
                                    clear statements and open scientific evidence absolutely clear, it completely invalidates all the material in the report generalising
                                    about HRT, because Prempro is totally unrepresentative of any other product used for HRT
                                    purposes. Provera (artificial
                                    progestogen) has crucially different effects to the natural hormone progesterone. And Premarin has different effects to the
                                    natural hormone estradiol.    The literature has detailed those, and explained them,
                                    over many years. Much of it was known before the NIH chose to use Prempro in its intended
                                    landmark study. Using a study of the effects of Prempro to attack
                                    the entire use of HRT has, through needless fear, caused millions of women to forgo considerable benefits of HRT using better
                                    products. This point has been repeatedly made by endocrinologists.
                                    Why does Nature not know it?--END OF ARTICLE. This published comment appeared in a section on
                                    the pervasive practice of pharmaceutical companies hiring companies that specializes in ghost writing.  These companies
                                    produce books, journal articles, news releases, lecture materials with the supposed review of these materials by the researchers
                                    whose name appears thereon or who gives the lecture--jk.  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 
                                    Hormone
                                    Hysteria ---Scientific American, Dennis Watkins, 9/2003, edited by jk http://www.scientificamerican.com/article.cfm?id=hormone-hysteria
                                     …Postmenopausal women
                                    have for decades relied on estrogen supplements to control the hot flashes,
                                    memory loss, osteoporosis and other ailments that can occur when their bodies
                                    no longer produce the compound. But hormone replacement therapy (HRT) is no
                                    longer considered the best way to treat menopause, ever since a report last year
                                    found that women receiving a certain type of HRT were at increased risk for
                                    dangerous side effects, such as breast cancer. Many health professionals have concluded that
                                    altering a woman's physiology will always increase risks over time. But a
                                    handful of respected scientists are calling for another look at HRT, arguing that not all therapies are created equal. … A RESEARCH STATES: 
                                    "I
                                    think that it borders on a tragedy that Premarin and Provera were chosen as the
                                    only HRT treatments."   {AS JK STATED ABOVE IT IS THE PROSTOGLANDIN
                                    in Provera & Premarin that caused the serious side effects}  
                                    Another researcher finds that hat Provera--and no other progestin--blocks the
                                    mechanisms that allow estrogen to fight the brain's immune response to
                                    Alzheimer's. This immune response wears away at brain cells and causes them
                                    to leak neurotransmitters such as glutamate, which overloads and kills neurons.
                                    "It's basically as if someone were to open your mouth and shove down
                                    gallons" of soft drink, Brinton explains. "It's caustic, and you can't
                                    metabolize it enough."  {After the usual
                                    journalistic waffling, the Scientific American articles gets to the issue}  For many scientists, a critical question
                                    yet
                                    remains: To what extent do the results of the initiative study apply to other
                                    forms of hormone replacement? "We cannot be sure whether other hormone
                                    combinations will have the same effects," Rossouw cautions, "but in
                                    my opinion we should assume they do until proven otherwise." But
                                    neuroendocrinologist Bruce S. McEwen of the Rockefeller University is
                                    unequivocally critical of the study: "I think that it borders on a
                                    tragedy that Premarin and Provera were chosen as the only HRT treatments."
                                     A growing number of
                                    researchers believe that Provera is a poor substitute for progesterone. For
                                    example, medroxyprogesterone will bind in the
                                    breasts to progesterone receptors, which causes
                                    breast cells to divide after puberty and during the menstrual cycle, and also
                                    to glucocorticoid receptors, which causes cell division during pregnancy. This
                                    double-barreled assault on breast cells, explains C. Dominique Toran-Allerand,
                                    a developmental neurobiologist at Columbia University, probably led to the high
                                    rates of breast cancer in the study. "With Provera
                                    you are activating two receptors involved
                                    with cell division in the breast," she says, "and that's the culprit,
                                    not estrogen."  In addition, recent research shows that Provera interferes with estrogen's ability to prevent
                                    memory loss
                                    and dementia. "Estrogen is able
                                    to protect neurons against toxic assaults that are associated with Alzheimer's
                                    disease," notes Roberta Diaz Brinton, a neuroscientist at the University
                                    of Southern California. Using in vitro studies of several types of progestin,
                                    she found that Provera--and no other progestin--blocks the mechanisms that allow
                                    estrogen to fight the brain's immune response to Alzheimer's. This
                                    immune response wears away at brain cells and causes them to leak
                                    neurotransmitters such as glutamate, which overloads and kills neurons.
                                    "It's basically as if someone were to open your mouth and shove down
                                    gallons" of soft drink, Brinton explains. "It's caustic, and you
                                    can't metabolize it enough."  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 
                                    Past long-term estrogen
                                    use decreases Alzheimer’s disease in older women (83% for over 10 years)  December 2002 report of NAMS (North American Menopause Society) Zandi PP, Carlson MC,
                                    Plassman BL, et al, for the Cache County Memory Study Investigators. Hormone
                                    replacement therapy and incidence of Alzheimer disease in older women: the
                                    Cache County study. JAMA 2002;288:2123-2129.  Use of hormone therapy
                                    is associated with a reduced risk of Alzheimers disease (AD), especially use
                                    for longer than 10 years, according to results from this prospective
                                    observation al study conducted in Cache County (Logan, Utah). A total of 1,889
                                    women (mean age, 74.5 years) were enrolled. A similarly aged group of men (n =
                                    1,357) served as controls. History of hormone therapy use (either estrogen
                                    alone or estrogen plus a progestogen), as well as intakes of calcium and
                                    multivitamin supplements, were assessed at baseline. After 3 years of
                                    follow-up, 88 women (4.7%) and 35 men (2.6%) had developed AD. Women aged 80
                                    and older had more than twice the rate of AD as men of that age (hazard ratio
                                    [HR], 2.11; 95% CI, 1.22-3.86). Overall, hormone therapy significantly reduced
                                    the risk of AD by 41% compared with nonusers (95% CI, 0.36-0.96). Hormone use
                                    for at least 10 years resulted in a 69% reduction in risk (95% CI, 0.17-0.86), which was statistically
                                    the same as the risk for matched males. When the results were assessed by
                                    current and former hormone use, current use (72% unopposed estrogen) was not
                                    associated with decreased AD risk unless the duration of treatment exceeded 10
                                    years. For former users, 3 or more years of use significantly reduced the AD
                                    risk, with more than 10 years use reducing the risk by 83% (95% CI, 0.01-0.80). No similar effects were
                                    seen with either calcium or multivitamin use.  NOTE: 
                                    the results are based taking the best
                                    combination, other studies using different combinations obtain lower results
                                    and those with Prempro no benefit. A earlier (1999) NAMS meta-study, not
                                    separating types of HRT or duration of usage found a 29% reduction--jk.   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^Molecualr Pharmacology, April 1,
                                    1997 vol. 51, no. 4, 535-541Neuroprotection
                                    against Oxidative Stress by Estrogens: Structure-Activity RelationshipAbstractOxidative stress-induced neuronal cell death has been implicated in
                                    different neurological disorders and neurodegenerative diseases; one such
                                    ailment is Alzheimer’s disease. Using the Alzheimer’s disease-associated
                                    amyloid β protein, glutamate, hydrogen peroxide, and buthionine sulfoximine, we
                                    investigated the neuroprotective potential of estrogen against oxidative
                                    stress-induced cell death. We show that 17-β-estradiol, its nonestrogenic
                                    stereoisomer, 17-α-estradiol, and some estradiol derivatives can prevent
                                    intracellular peroxide accumulation and, ultimately, the degeneration of
                                    primary neurons, clonal hippocampal cells, and cells in organotypic hippocampal
                                    slices. The neuroprotective antioxidant activity of estrogens is dependent on
                                    the presence of the hydroxyl group in the C3 position on the A ring of the
                                    steroid molecule but is independent of an activation of estrogen receptors.  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ 8% Reduced Risk of Thrombosis with Esterfied
                                    Estrogen Only Esterified
                                    Estrogens and Conjugated Equine Estrogens and the Risk of Venous ThrombosisJAMA (the Journal of the American
                                    Medical association) 2004;292(13):1581-1587. doi: 10.1001/jama.292.13.1581 At http://jama.ama-assn.org/content/292/13/1581.abstract
                                     
                                     1.      Rosendaal).Nicholas
                                            L. Smith, PhD; Susan
                                            R. Heckbert, MD, PhD;  Rozenn
                                            N. Lemaitre, PhD; Alex
                                            P. Reiner, MD, MPH; Thomas
                                            Lumley, PhD; Noel
                                            S. Weiss, MD, DrPH; Eric
                                            B. Larson, MD, MPH; Frits
                                            R. Rosendaal, MD; Bruce
                                            M. Psaty, MD, PhD 
                                     Corresponding
                                         Author: Nicholas L. Smith, PhD, Cardiovascular Health
                                         Research Unit, 1730 Minor Ave, Suite 1360, Seattle, WA 98101 (nlsmith@u.washington.edu).  AbstractContext:  Clinical trial evidence indicates that
                                    estrogen therapy with or without progestins increases venous thrombotic risk.
                                    The findings from these trials, which used oral conjugated equine estrogens,
                                    may not be generalizable to other estrogen compounds.  Objective:  To compare risk of venous thrombosis among
                                    esterified estrogen users, conjugated equine estrogen users, and nonusers.  Design, Setting, and Participants  This
                                    population-based, case-control study was conducted at a large health
                                    maintenance organization in Washington State. Cases were perimenopausal and
                                    postmenopausal women aged 30 to 89 years who sustained a first venous
                                    thrombosis between January 1995 and December 2001 and controls were matched on
                                    age, hypertension status, and calendar year.  Main Outcome Measure:  Risk of first venous thrombosis
                                    in relation to current use of esterified or conjugated equine estrogens, with
                                    or without concomitant progestin. Current use was defined as use at thrombotic
                                    event for cases and a comparable reference date for controls.  Results:  Five hundred eighty-six incident venous
                                    thrombosis cases and 2268 controls were identified. Compared with women not
                                    currently using hormones, current users of esterified estrogen had no increase in
                                    venous thrombotic risk (odds ratio [OR], 0.92*; 95% confidence interval [CI],
                                    0.69-1.22). In contrast, women currently taking conjugated equine estrogen had
                                    an elevated risk (OR, 1.65; 95% CI, 1.24-2.19). When analyses were restricted
                                    to estrogen users, current users of conjugated equine estrogen had a higher
                                    risk than current users of esterified estrogen (OR, 1.78; 95% CI, 1.11-2.84).
                                    Among conjugated equine estrogen users, increasing daily dose was associated
                                    with increased risk (trend P value   = .02). Among all estrogen
                                    users, concomitant progestin use was associated with increased risk compared
                                    with use of estrogen alone (OR, 1.60; 95% CI, 1.13-2.26).  * Not “no
                                    increase” but rather reduces 8%--jk. Conclusion:  Our finding that conjugated equine
                                    estrogen but not esterified estrogen was associated with venous thrombotic risk
                                    needs to be replicated and may have implications for the choice of hormones in
                                    perimenopausal and postmenopausal women.  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ 
 Decrease
                                    in breast cancer found for the use of estrogen and progesterone compared to those who never
                                    used HRT; the same risk if estrogen and dydrogesterone, and a marked increase with estrogen and progestins such as with Prempro
                                    (NAMS study above).  This failure to consider adequately consider other combinations
                                    that that in Prempro entails that the WHI study has limited scope--jk.    
                                     From Wikipedia  Women’s Health Initiative WHI study (the one used to get women
                                    off of HRT) The Women's Health
                                    Initiative (WHI) was initiated by the National Institutes of Health (NIH) in 1991. The objective of this women's health research initiative was to conduct medical
                                    research into some of the major health problems of older women. In particular, randomized controlled trials were designed and funded that address cardiovascular disease, cancer, and osteoporosis. Study componentsThere are actually 4 different randomized interventions
                                    and a separate observational-only cohort in the WHI. All 4 of the randomized components overlap with each other to some extent
                                    (and a few even overlap with the observational study). The 4 interventions and their abbreviated terminology are: Estrogen-progestin versus
                                    placeboThis phase studied estrogen, specifically conjugated equine estrogen, plus progestin (Prempro, Wyeth) compared to placebo (the "WHI-E+P" trial), among healthy postmenopausal women. This trial found that, compared with placebo,
                                    women receiving equine estrogen plus progestin experienced:[1] The trial was ended early in 2002 when the researchers
                                    found that the subjects with estrogen plus progestin had a greater incidence of coronary heart disease, breast cancer, stroke,
                                    and pulmonary embolism than the subjects receiving placebo.[2] Hormone replacement therapy use declined in the U.S. and around the world, followed by a decline in breast cancer.[3] Conjugated estrogen
                                    versus placeboThis trial studied estrogen, specifically conjugated equine estrogen (Premarin, Wyeth), alone versus placebo (the "WHI-CEE" trial) in women with prior hysterectomy. The trial was conducted among women with hysterectomy
                                    so that estrogen could be administered without a progestin. In women with a uterus, a progestin is needed to counteract the
                                    risk of endometrial cancer posed by unopposed estrogen. Major results of this study were than, compared
                                    with placebo, women receiving {equine} estrogen alone experienced:[1] 
                                    no difference in risk for myocardial infarction 
                                    an increased risk of stroke 
                                    an increased risk of blood clots
                                    
                                    an uncertain effect on breast cancer
                                    risk 
                                    no difference in risk for colorectal cancer 
                                    a reduced risk of fracture 
                                    {with esterifed estrogen all of the above categories are significantly more favorable--jk} Calcium and vitamin
                                    D versus placeboThis trial compared calcium plus vitamin D versus placebo
                                    ("WHI-CalcVitD"). This had 2 major papers arise from it in NEJM 2006, and one in May 2007 in the Archives of Internal Medicine [1]: 
                                    CRC endpoint 
                                    Fracture endpoint Non-intervention cohortThe non-interventional observational cohort study ("WHI-OS")
                                    observed 93,000 women drawn from the same national clinical coordinating centers (many epidemiology studies conducted within this observational component of the WHI). The WHI Postmenopausal Hormone Therapy Trials were part of the effort to address the high risk of cardiovascular disease in older women. By the early 1990s, many physicians had come to interpret results from
                                    previous clinical trials and studies using experimental animals as indicating that administration of an estrogen supplement to postmenopausal women would lower the incidence of cardiovascular disease.
                                    Two hormone clinical trials were designed and conducted: The estrogen that was administered in the WHI studies
                                    was conjugated equine estrogen (CEE). This consists
                                    of a mixture of estrogens isolated from horse urine (Premarin). The CEE was administered orally. Both studies were randomized, placebo-controlled
                                    studies. Half the women were given an inactive placebo rather than hormone(s). Both studies were terminated early because
                                    a reduction in cardiovascular disease was not observed for most women and some women had dangerous side-effects. In particular,
                                    an increased risk of dangerous blood clotting is associated with oral administration of CEE. A review of the observational and WHI estrogen trial results describes potential explanations for the conflicting results. In addition, co-administration of MPA (medroxyprogesterone acetate, a type of progestin) with CEE was associated with a slightly increased risk
                                    of breast cancer. Some benefits of using an estrogen supplement such as reduced risk of bone fractures were confirmed by these
                                    studies. However, for the older postmenopausal women who were recruited for this study, the undesirable side-effects of treatment
                                    generally were greater than the health benefits. Based on the results of these studies, CEE and MPA are no longer given to
                                    women in order to try to prevent cardiovascular disease in older women. Younger postmenopausal women seeking relief from conditions
                                    such as hot flashes, sleep disturbance and urinary/vaginal atrophy are still candidates for hormone replacement therapy. Alternatives
                                    to orally administered CEE and MPA are being increasingly used by women since the termination of the WHI studies. For example,
                                    other forms of estrogen (such as esterified estrogens) or topical
                                    administration of estradiol may reduce the risk of blood clotting compared to that for oral CEE.[4] Finally, the low fat dietary pattern trial of the WHI
                                    yielded conflicting and controversial results. However, the WHI trial has been argued as unnecessary by many scientists, who
                                    already knew a full decade ago that total fat intake is not related to cardiovascular risk nor postmenopausal breast cancer
                                    risk. WIKIPEDIA ON HRT: Wikipedia, the best single source on evidence-based, scholarly, information
                                    on drugs, diseases, conditions, and treatments confirms my research.  On their estrogen articles:  Estrogen and other hormones are given to postmenopausal
                                    women in order to prevent osteoporosis as well as treat the symptoms of menopause
                                    such as hot flushes, vaginal dryness, urinary stress incontinence, chilly
                                    sensations, dizziness, fatigue, irritability, and sweating. Fractures of the
                                    spine, wrist, and hips decrease by 50–70% and spinal bone density increases by
                                    ~5% in those women treated with estrogen within 3 years of the onset of
                                    menopause and for 5–10 years thereafter. Before the specific dangers of conjugated equine estrogens were well understood,
                                    standard therapy was 0.625 mg/day of conjugated equine estrogens (such as
                                    Premarin). There are, however, risks associated with conjugated equine estrogen
                                    therapy. Among the older postmenopausal women studied as part of the Women's Health Initiative (WHI), an
                                    orally administered conjugated equine estrogen supplement was found to be
                                    associated with an increased risk of dangerous blood
                                       clotting. The WHI studies used one type of estrogen supplement, a high oral
                                    dose of conjugated equine estrogens (Premarin alone
                                    and with medroxyprogesterone acetate as PremPro).[29] In a study by the NIH, esterified estrogens were not proven to pose the same
                                    risks to health as conjugated equine estrogens. Hormone replacement therapy
                                    has favorable effects on serum cholesterol levels, and when initiated
                                    immediately upon menopause may reduce the incidence of cardiovascular disease,
                                    although this hypothesis has yet to be tested in randomized trials. Estrogen
                                    appears to have a protector effect on atherosclerosis: it lowers LDL and
                                    triglycerides, it raises HDL levels and has endothelial vasodilatation
                                    properties plus an anti-inflammatory component.
                                     |